ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADMA Biologics, Inc. on February 28, 2020. The report details the Board of Directors' approval of 2020 base salaries and 2019 performance-based compensation for the Company's named executive officers.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
On February 28, 2020, the Board approved the following compensation packages for named executive officers, reflecting the achievement of 125% of the Company's 2019 corporate goals:
| Officer | Position | 2020 Base Salary | 2019 Cash Bonus | RSUs Granted | Stock Options Granted |
|---|---|---|---|---|---|
| Adam S. Grossman | President, CEO, Director | $600,000 | $368,500 | 100,000 | 325,000 |
| Dr. James Mond | EVP, CSO, CMO | $440,000 | $207,500 | 40,000 | 100,000 |
| Brian Lenz | EVP, CFO | $420,000 | $195,000 | 40,000 | 100,000 |
Equity Terms:
- RSUs: Vest quarterly over four years from the grant date.
- Stock Options: Exercise price of $2.915 per share. Vesting schedule includes 25% on the one-year anniversary and the remaining 75% monthly over the subsequent three years, fully vested by February 28, 2024.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure of the compensation plan terms. The cash bonuses are scheduled for payment in early March 2020.
Key Facts for Investor Verification
- Verify the total cash outflow for the 2019 performance bonuses ($771,000 total) and its impact on Q1 2020 cash flow.
- Confirm the dilution impact of the 565,000 new stock options and 180,000 RSUs granted to executives.
- Review the specific 2019 corporate goals and milestones that were achieved at 125% to validate the bonus calculation.
- Check the Company's current cash position to ensure liquidity is sufficient to cover the upcoming bonus payments in March 2020.